KDM6A and chronic myelogenous leukemia, BCR-ABL1 positive: Moreover, this mechanism was shown to be relevant to imatinib-selected CML cells expressing elevated levels of BCR-ABL, collectively indicating that KDM6A fulfils an intrinsic survival role for CML cells upon inhibition of BCR-ABL signaling.